Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma. 

Harada S, Ando M, Ando J, Ishii M, Yamaguchi T, Yamazaki S, Toyota T, Ohara K, Ohtaka M, Nakanishi M, Shin C, Ota Y, Nakashima K, Ohshima K, Imai C, Nakazawa Y, Nakauchi H, Komatsu N. Mol Ther. 2022 Feb 2;30(2):534-549. doi: 10.1016/j.ymthe.2021.10.006. Epub 2021 Oct 8.PMID: 34628050

Harada S, Ando M, Ando J, Ishii M, Yamaguchi T, Yamazaki S, Toyota T, Ohara K, Ohtaka M, Nakanishi M, Shin C, Ota Y, Nakashima K, Ohshima K, Imai C, Nakazawa Y, Nakauchi H, Komatsu N.

Mol Ther. 2022 Feb 2;30(2):534-549. doi: 10.1016/j.ymthe.2021.10.006. Epub 2021 Oct 8.PMID: 34628050

asami.miyamoto

Previous
Next

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts